The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
Justin Klee
Advertisement
Articles by Justin Klee
Advertisement
Latest Updated Articles
Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BScPublished: May 19th 2022 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Long-Term Data Suggest Friedreich Ataxia Agent Omaveloxolone Slows Disease Progression Over 4 Years
2
N-Acetyl-L-Leucine Reduces Disease Progression in Phase 2 Extension Study for Ataxia-Telangiectasia
3
Stopping Therapy in Multiple Sclerosis and DISCOMS Trial: Long-Term Strategies
4
Managing Infection Risks and Treatment De-Escalation in Patients on Long-Term Anti-CD20 Therapies in Multiple Sclerosis
5
